2020
An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib.
Sharma R, Hajiev S, Aval L, Bettinger D, Arizumi T, Pirisi M, Rimassa L, Personeni N, Pressiani T, Giordano L, Kudo M, Thimme R, Park J, Taddei T, Kaplan D, Ramaswami R, Pinato D, Allara E. An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib. Journal Of Clinical Oncology 2020, 38: 12049-12049. DOI: 10.1200/jco.2020.38.15_suppl.12049.Peer-Reviewed Original ResearchOverall survivalStarting doseHepatocellular carcinomaAdvanced-stage hepatocellular carcinomaLower starting doseSorafenib-related toxicityMedian overall survivalMulticentre cohort studyPortal vein thrombosisTerms of OSLow-dose therapyDose of sorafenibRates of toxicitySorafenib dosingSorafenib toxicityChild-PughDose therapyCohort studyElderly patientsOlder patientsVein thrombosisClinical efficacySimilar incidenceSpecialist centresLarge tumors
2017
Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES
Butt AA, Ren Y, Re V, Taddei T, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clinical Infectious Diseases 2017, 65: 64-72. PMID: 28369305, DOI: 10.1093/cid/cix224.Peer-Reviewed Original ResearchConceptsHCV-positive personsHepatic decompensationFIB-4 scoreHuman immunodeficiency virusFIB-4Hepatocellular carcinomaCause mortalityLower riskHCV diagnosisClinical outcomesHepatitis C virus-infected personsHepatitis B surface antigenCohort of HCVVirus-infected personsB surface antigenHepatitis C virusChild-TurcotteChild-PughEarly complicationsMELD scoreImmunodeficiency virusC virusIncidence ratePositive personsTreatment decisions